UPLOAD Filing
Tenaya Therapeutics, Inc.
Date: Sept. 10, 2025 · CIK: 0001858848 · Accession: 0000000000-25-009790
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-40656
Letter
Re: Tenaya Therapeutics, Inc. Form 10-K for the Year Ended December 31, 2024 File No. 001-40656 Dear Faraz Ali:
September 10, 2025
Faraz Ali Chief Executive Officer Tenaya Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 500 South San Francisco, CA 94080
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: Jennifer Drimmer, J.D.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 10, 2025 Faraz Ali Chief Executive Officer Tenaya Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 500 South San Francisco, CA 94080 Re: Tenaya Therapeutics, Inc. Form 10-K for the Year Ended December 31, 2024 File No. 001-40656 Dear Faraz Ali: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Drimmer, J.D. </TEXT> </DOCUMENT>